Literature DB >> 31822220

Radiation protraction schedules for low-grade gliomas: a comparison between different mathematical models.

I Budia1, A Alvarez-Arenas1, T E Woolley2, G F Calvo1, J Belmonte-Beitia1.   

Abstract

We optimize radiotherapy (RT) administration strategies for treating low-grade gliomas. Specifically, we consider different tumour growth laws, both with and without spatial effects. In each scenario, we find the optimal treatment in the sense of maximizing the overall survival time of a virtual low-grade glioma patient, whose tumour progresses according to the examined growth laws. We discover that an extreme protraction therapeutic strategy, which amounts to substantially extending the time interval between RT sessions, may lead to better tumour control. The clinical implications of our results are also presented.

Entities:  

Keywords:  low-grade glioma; mathematical models; optimization problem; radiotherapy

Year:  2019        PMID： 31822220      PMCID： PMC6936034          DOI： 10.1098/rsif.2019.0665

Source DB:  PubMed          Journal:  J R Soc Interface        ISSN： 1742-5662            Impact factor:   4.118


  47 in total

1.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

Authors:  Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran
Journal:  N Engl J Med       Date:  2016-04-07       Impact factor: 91.245

2.  Extreme protraction for low-grade gliomas: theoretical proof of concept of a novel therapeutical strategy.

Authors:  Víctor M Pérez-García; Luis A Pérez-Romasanta
Journal:  Math Med Biol       Date:  2015-05-11       Impact factor: 1.854

Review 3.  Advances in the molecular genetics of gliomas - implications for classification and therapy.

Authors:  Guido Reifenberger; Hans-Georg Wirsching; Christiane B Knobbe-Thomsen; Michael Weller
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

4.  Modelling biological invasions: Individual to population scales at interfaces.

Authors:  J Belmonte-Beitia; T E Woolley; J G Scott; P K Maini; E A Gaffney
Journal:  J Theor Biol       Date:  2013-06-13       Impact factor: 2.691

5.  A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects.

Authors:  Lara Barazzuol; Neil G Burnet; Raj Jena; Bleddyn Jones; Sarah J Jefferies; Norman F Kirkby
Journal:  J Theor Biol       Date:  2009-10-17       Impact factor: 2.691

6.  Three-dimensional multispecies nonlinear tumor growth--I Model and numerical method.

Authors:  S M Wise; J S Lowengrub; H B Frieboes; V Cristini
Journal:  J Theor Biol       Date:  2008-03-28       Impact factor: 2.691

7.  Late Effects After Radiotherapy for Childhood Low-grade Glioma.

Authors:  Noelle L Williams; Ronny L Rotondo; Julie A Bradley; David W Pincus; John A Fort; Tung Wynn; Christopher G Morris; Nancy P Mendenhall; Daniel J Indelicato
Journal:  Am J Clin Oncol       Date:  2018-03       Impact factor: 2.339

8.  Computational design of improved standardized chemotherapy protocols for grade II oligodendrogliomas.

Authors:  Víctor M Pérez-García; Luis E Ayala-Hernández; Juan Belmonte-Beitia; Philippe Schucht; Michael Murek; Andreas Raabe; Juan Sepúlveda
Journal:  PLoS Comput Biol       Date:  2019-07-15       Impact factor: 4.475

Review 9.  Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence.

Authors:  Hayley P Ellis; Mark Greenslade; Ben Powell; Inmaculada Spiteri; Andrea Sottoriva; Kathreena M Kurian
Journal:  Front Oncol       Date:  2015-11-16       Impact factor: 6.244

10.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Authors:  Brigitta G Baumert; Monika E Hegi; Martin J van den Bent; Andreas von Deimling; Thierry Gorlia; Khê Hoang-Xuan; Alba A Brandes; Guy Kantor; Martin J B Taphoorn; Mohamed Ben Hassel; Christian Hartmann; Gail Ryan; David Capper; Johan M Kros; Sebastian Kurscheid; Wolfgang Wick; Roelien Enting; Michele Reni; Brian Thiessen; Frederic Dhermain; Jacoline E Bromberg; Loic Feuvret; Jaap C Reijneveld; Olivier Chinot; Johanna M M Gijtenbeek; John P Rossiter; Nicolas Dif; Carmen Balana; Jose Bravo-Marques; Paul M Clement; Christine Marosi; Tzahala Tzuk-Shina; Robert A Nordal; Jeremy Rees; Denis Lacombe; Warren P Mason; Roger Stupp
Journal:  Lancet Oncol       Date:  2016-09-27       Impact factor: 54.433
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.